Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items

Similar documents
GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary

Ertugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy

Initiating Injectable Therapy in Type 2 Diabetes

Insulin Initiation and Intensification. Disclosure. Objectives

Incredible Incretins Abby Frye, PharmD, BCACP

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

GLP-1 receptor agonists for type 2 diabetes currently available in the U.S.

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.

Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol

The Many Faces of T2DM in Long-term Care Facilities

MOA: Long acting glucagon-like peptide 1 receptor agonist

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol

Achieving and maintaining good glycemic control is an

What s New in Diabetes Medications. Jena Torpin, PharmD

The Death of Sulfonylureas? A Review of New Diabetes Medications

Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D

Beyond A1C. Non-glycemic Effects of GLP-1 Receptor Agonists. Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015

See Important Reminder at the end of this policy for important regulatory and legal information.

GLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018

Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010

GLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK

Making Sense of New DM Therapies and Technologies

New Drug Evaluation: Dulaglutide

Learning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C

What to Do After Basal Insulin

Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: Last Review Date: 02.

GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.

DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!

Individualizing Care for Patients with Type 2 Diabetes

What s New in Type 2 Diabetes? 2018 Diabetes Updates

Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications

Newer Therapies for Type 2 Diabetes

Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes

Chief of Endocrinology East Orange General Hospital

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

The first stop for professional medicines advice

3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy

Injectable Agents for Type 2 Diabetes. Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017

What s New in Type 2 Diabetes? 2018 Diabetes Updates

4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis

IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS

Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM

2/9/2016. The Evolving Armamentarium for Type 2 Diabetes: Incorporating New Classes in the Treatment of Our Patients. Objectives: Pharmacists

Basal Insulin Use With GLP-1 Receptor Agonists

GLP-1-based therapies in the management of type 2 diabetes

Update on Insulin-based Agents for T2D

Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Presented By: Creative Educational Concepts, Inc. Lexington, KY

APPENDIX American Diabetes Association. Published online at

Disclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare

Comprehensive Diabetes Treatment

Diabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs

5/16/2018. Insulin Update: New and Emerging Insulins. Disclosures to Participants. Learning Objectives

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM

Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes

Position Statement of ADA / EASD 2012

Drug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists

Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018

Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

What s New in Diabetes Treatment. Disclosures

6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE

DM Fundamentals Class 4 Meds for Type 2

Next Steps for Clinicians

Application of the Diabetes Algorithm to a Patient

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

Francesca Porcellati

VICTOSA and Renal impairment DR.R.S.SAJAD

Multiple Factors Should Be Considered When Setting a Glycemic Goal

UKPDS: Over Time, Need for Exogenous Insulin Increases

Basal & GLP-1 Fixed Combination Use

STEP THERAPY CRITERIA

Table 1. Antihyperglycemic agents for use in type 2 diabetes

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach

INSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital

Date of Review: September 2016 Date of Last Review: September 2015

Inpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy

Type 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM

Disclosures. Overall Goals. Objectives. What s worth the PA forms for Patients in the Safety Net? None relevant

DEMYSTIFYING INSULIN THERAPY

ADA and AACE Glycemic Targets

Xultophy 100/3.6. (insulin degludec, liraglutide) New Product Slideshow

NEW DIABETES CARE MEDICATIONS

New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011

OBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting

Progressive Loss of β-cell Function in T2DM

Disclosures of Interest. Publications Diabetologia Key points to emphasize

EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens

Selecting GLP-1 RA Treatment

9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends

Intensification of Diabetic Therapy. Case studies

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

DM Fundamentals Class 4 Meds for Type 2

Adlyxin. (lixisenatide) New Product Slideshow

New Drug Evaluation: lixisenatide injection, subcutaneous

Update on Insulin-based Agents for T2D. Harry Jiménez MD, FACE

Insulin Intensification: A Patient-Centered Approach

Transcription:

Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Hayley A. Miller, MD Physician, Internal Medicine, Diabetes and Metabolism, Sandy Clinic, Intermountain Healthcare Objectives: Identify when prandial insulin should be initiated Discuss the different options for post-prandial blood glucose control Describe the advantages and disadvantages of different prandial therapies

Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items HAYLEY MILLER, MD THE SANDY CLINIC PRIMARY CARE CONFERENCE FEBRUARY September 11, 2015

Objectives Following today s presentation, the provider should be able to: Discuss WHY patients need therapeutic intensification after basal insulin. Identify WHEN therapeutic intensification is indicated. Review HOW to target post prandial hyperglycemia using several different strategies including: : GLP 1 receptor agonists Subcutaneous rapid acting insulin Have time for questions (and avoid tangents)

Introduction

The Cost of Hyperglycemia 29.1 million people in the US have been diagnosed with diabetes 37% of US adults >20 years old have pre diabetes The annual cost of health care for diabetes is ~$245 billion Diabetes is the leading cause dialysis and non traumatic lower limb amputations. Diabetes is the 7 th leading cause of death in the US. National Diabetes Statistics Report, 2014. National Center for Chronic Disease Prevention and Health Promotion.

Why intensify therapy after basal insulin?

Percent of Your Patients Achieving HbA1c <8% in One Year

This means 58% of patients are NOT achieving their glycemic targets.

Medications for Type 2 Diabetes: General Recommendations 2012 by American Diabetes Association Inzucchi S E et al. Dia Care 2012;35:1364-1379

When to intensify after basal insulin?

Natural History of Type 2 Diabetes Adapted from International Diabetes Center, Minneapolis MN.

Daily Insulin Requirements (Hypothetical 100 kg pt) 1 unit/kg (100 units) 0.75 units/kg (75 units) ~0.5 units/kg (50 units)

OVERBASALIZATION = Hypoglycemia and Weight Gain Increasing basal insulin without addition of prandial coverage requires the patient to eat for the insulin. The ideal basal dose should allow a patient to fast for 24 hours without hypoglycemia

When to Add Prandial Coverage? When basal insulin dose is about 0.5 units/kg/day OR HbA1c is not at goal despite appropriate fasting blood glucose values.

HOW to Intensify After Basal Insulin?

Post-prandial Hyperglycemia: Option 1 GLP-1 Receptor Agonists

Glucagon Like Protein 1 Receptor Agonists (GLP-1 RAs)

GLP-1 RA: New Alternative to Prandial Insulin * When studied as add on to basal insulin compared to rapid acting insulin analogues, GLP 1RAs demonstrated: Comparable HbA1c reductions Weight loss instead of weight gain Fewer hypoglycemic events Possible improvement in patient quality of life * Diamant et al. Diabetes Care 2014; 37: 2763 73 * Rosenstock J et al. Diabetes Care 2014; 37(8):2317 25

GLP-1 RA Formulations Drug Dose Increments Administration Byetta (exenatide) 5 10 mcg Twice daily Bydureon (exenatide) 2 mg Weekly Victoza (liraglutide) 0.6 1.8 mg Daily Tanzeum (albiglutide) 30 50 mg Weekly Trulicity (dulaglutide) 0.75 1.5mg Weekly

Contraindications Severe gastroparesis History of pancreatitis not attributable to gallstones Personal or family history of medullary thyroid carcinoma MEN Type 2 Severe GI disease Creatinine clearance <30 mg/dl

Practical Considerations: HOW to Add GLP-1 RA to Basal Insulin Discontinue sulfonylurea If HbA1c <8%, basal insulin by 10 20% until maximal tolerated dose achieved. Start with lower dose. Titrate weekly as tolerated. THEN titrate basal insulin. Nurse/MA should provide face to face education about dose administration. TIP: Providing discount co pay cards and ensuring that you prescribe the GLP 1RA preferred by patient insurance augments adherence.

Post-prandial Hyperglycemia: Option 2 Rapid Acting Insulin

Basal Plus Approach

Intensification Strategy with SQ RAIA Add 3 4 units RAIA at largest meal of day and continue with basal insulin Add 1 2 extra units RAIA every week if post prandial BG >180 mg/dl Continue titration until post prandial BG <180 mg/dl If HbA1c is not at goal after 3 months, add 2 nd injection RAIA at 2 nd largest meal of the day

Approach to starting and adjusting insulin in type 2 diabetes. Inzucchi S E et al. Dia Care 2015;38:140-149 2015 by American Diabetes Association

In Summary

Intensification is Important for T2DM Therapy should be intensified when basal insulin dose is approximately 0.5 units/kg OR a patient is not achieving target HbA1c despite appropriate FBG. There are several options for intensification. Selection thereof should be individualized for each patient. GLP 1RA can be dosed BID, QD or Qweek, is associated with weight loss, less hypoglycemia, and typically reduced basal insulin dose. Subcutaneous RAIA can be started once daily prior to largest meal and titrated as needed to achieve glycemic goals.

Advantages and Disadvantages of Therapies Therapy Advantages Disadvantages GLP 1 Receptor Agonist Hypoglycemia weight post prandial glucose excursion some CV risk factors GI side effects (n/v/d) HR? Pancreatitis C cell hyperplasia/medullary TC (rats) Injectable SQ Rapid Acting Insulin Nearly universal response Theoretically unlimited efficacy microvascular risk (UKPDS) Hypoglycemia Weight gain Injectable Patient reluctance

Questions?

Two Strategies for Insulin Intensification GLP 1 RA SQ RAIA Dose schedule QD, BID, Qweek QD, BID, TID HbA1c Reduction ++ +++ Weight Hypoglycemia + +++ Contraindications Medullary thyroid cancer Pancreatitis Cr/Cl <30 mg/dl NA